ndothelins (ET) are 21-amino-acid peptides produced by the endothelium and which play important roles in cardiovascular physiology and pathophysiology. 1 The most important ET produced by the endothelium is ET-1, which has an important role in the vasoconstriction of the peripheral arterial system and also of the coronary vascular bed. 2 Elevated plasma concentrations of ET have been observed in patients suffering from diverse cardiovascular diseases, such as congestive heart failure, 3-5 pulmonary hypertension 6 and angina pectoris. [7] [8] [9] In patients with acute myocardial infarction (AMI) particularly, the cardiac ET system is markedly activated 10, 11 and plasma concentrations of ET-1 are elevated. 12 Little is known, however, about the relationship between plasma ET-1 concentrations, mortality and left ventricular (LV) systolic function in human AMI subjects.
ndothelins (ET) are 21-amino-acid peptides produced by the endothelium and which play important roles in cardiovascular physiology and pathophysiology. 1 The most important ET produced by the endothelium is ET-1, which has an important role in the vasoconstriction of the peripheral arterial system and also of the coronary vascular bed. 2 Elevated plasma concentrations of ET have been observed in patients suffering from diverse cardiovascular diseases, such as congestive heart failure, [3] [4] [5] pulmonary hypertension 6 and angina pectoris. [7] [8] [9] In patients with acute myocardial infarction (AMI) particularly, the cardiac ET system is markedly activated 10, 11 and plasma concentrations of ET-1 are elevated. 12 Little is known, however, about the relationship between plasma ET-1 concentrations, mortality and left ventricular (LV) systolic function in human AMI subjects.
The object of the present study was to determine whether clinical prognosis after AMI may be predicted from acutephase plasma ET-1 concentrations, and to assess whether there might be any relationship between plasma ET-1 concentrations and LV systolic function.
Methods

Patient Population
The study population comprised 110 consecutive patients (79 males, 31 females; 68±11 years, range 40-93) presenting with a first AMI, admitted and enrolled between March 2003 and June 2004. Diagnosis of AMI was done according to the following criteria: (1) complaint of chest pain and/or discomfort; (2) electrocardiographic ST segment elevation of ≥0.1 mV in 2 or more limb leads, or ≥0.2 mV in 2 or more precordial leads, or new left bundlebranch block; and (3) elevation of total serum creatine kinase (CK) more than twice the upper limit of the normal range. We excluded patients with renal failure on admission (serum creatinine >2.5 mg/dl), patients with old myocardial infarction (MI), patients who reached the institution >6 h after onset, and patients who died <24 h after onset (ie, at the time of blood sampling). We diagnosed anterior MI in 54 patients. Subjects were divided into 2 groups according to the median plasma ET-1 concentration: <2.9 pg/ml (L group, n=55) and ≥2.9 pg/ml (H group, n=55). We distinguished between angina pectoris episodes <24 h before the onset of AMI from general angina pectoris, to take into account ischemic pre-conditioning.
Treatment Strategy
Following oral administration of 200 mg of aspirin and 200 mg of ticlopidine, all patients successfully underwent direct percutaneous coronary intervention (PCI) within 8 h of the onset of symptoms. In 18 patients, conventional plain old balloon angioplasty was sufficient and the remaining 92 underwent coronary stenting. As a result, all patients attained Thrombolysis in Myocardial Infarction (TIMI) grade III flow. For 72 h after reperfusion therapy, all patients were given intravenous heparin (10,000 units/day) and either an angiotensin-converting enzyme inhibitor (quinapril 5 mg/day) or an angiotensin II receptor blocker (losartan, 50 mg/day) from the day after onset.
Blood Sampling
Twenty-four hours after onset, blood samples were taken from all subjects while they were supine. ET-1 concentrations were evaluated by immunoradiometric assay. Brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and highly sensitive C-reactive protein (hs-CRP) were all assessed from the same blood samples. CK was serially determined every 4 h after admission, for 3 days, and the peak value (peak-CK) was used as an indication of infarct size.
Hemodynamics and Cardiac Function
All subjects underwent left ventriculography while in the chronic (21±8 days after onset) phase, using a single plane with a right anterior deviation of 30°to evaluate LV ejection fraction (LVEF), calculate LV end-diastolic volume index (LVEDVI) using the area -length method, and to evaluate regional wall motion (RWM), using the centerline method. 13 We excluded posterior infarctions from the evaluation because of the associated issues of inaccuracy. We also assessed LV end-diastolic pressure (LVEDP) at that time. We used the Rentrop classification to evaluate collateral circulation before recanalization, and the TIMI classification to evaluate epicardial coronary flow. On admission, we used the Killip classification to assess the severity of the patient's condition. We monitored ST-segment elevation resolution on ECG to evaluate microvascular reperfusion injury. We also evaluated major complications, defined as cardiac rupture, ventricular arrhythmia (except reperfusion arrhythmia), pulmonary edema, cardiogenic shock, and cardiac death. We defined cardiogenic shock as blood pressure <90 mmHg (without inotropic or intra-aortic balloon support), signs of hypoperfusion (cold extremities, impaired mental status, or urine output <30 ml/h), and evidence of pulmonary congestion on chest X-ray.
ECG Analysis
ST-segment elevation was measured 0.08 s after the J point. The sum of ST-segment elevations ( ST) was obtained from leads I, aVL, and V1-6 for left anterior descending artery occlusions and from leads II, III, aVF, V5, V6 and reciprocal ST segment depressions in V1 and V2 for right coronary artery and left circumflex artery occlusions. ST was calculated from 2 separate 12-lead ECG recordings, one just prior to and one at the conclusion of the coronary intervention. ST segment analysis was done by a single observer unaware of the clinical data. A reduction of at least 50% in the ST segment elevation between the preand post-PCI ECGs was considered to constitute significant ST-segment resolution.
Statistical Analysis
Values are expressed as mean ± standard deviation (SD). All statistical tests were 2-tailed, and a p-value <0.05 was considered statistically significant. The odds ratios and 95% confidence intervals were also calculated. Correlations between serial variables were analyzed using linear regression and a rank-correlation test, and a p-value <0.05 in addition to an absolute coefficient of correlation value of >0.4 was considered statistically significant. In this study, the cut-off point for ET concentration was chosen from the median value (2.9 pg/ml). To date, similar reports have selected cut-off points for cardiovascular peptides based on tertiles, quartiles or median values, as in this study. The reason why we used a median value was to obtain reliable and useful statistical data within the limits of the small size of the sample population.
Results
Patient characteristics for the 2 groups (H and L groups) are summarized in Table 1 . There were no significant differences between the 2 groups in terms of age, gender, time elapsed from onset, or the existence of pre-infarction angina pectoris within 24 h of onset. In terms of coronary risk factors, there were no significant differences in hypertension, hyperlipidemia, or current smoking, but we did observe significantly more patients with diabetes mellitus (DM) in the H group than in the L group (46% vs 25%, p<0.05). Table 2 shows a comparison of the laboratory findings for the 2 groups. Plasma concentrations of BNP, ANP, and hs-CRP were significantly higher in the H group than in the L group (BNP: 488±472 pg/ml vs 232±280 pg/ml, p<0.001; ANP: 76±88 pg/ml vs 42±61 pg/ml, p<0.05; hs-CRP: 3.48± Table 3 . Both BNP and hs-CRP showed a significant correlation with ET (BNP: r=0.48, p<0.001; hs-CRP: r=0.43, p<0.001). Hemodynamic data at the time of admission are shown in Table 4 . In the H group, heart rate was significantly higher than in the L group (86±22 beats/min vs 78±15 beats/min, p<0.05). There were no significant differences in terms of culprit vessel location, or the rate of use of coronary stents between the 2 groups. In terms of the clinical severity of heart failure on admission, there was a significantly higher incidence of severe heart failure (Killip III or IV) among H group patients than in their L group counterparts (p<0.01).
Major complication rates in the first 3 months are shown in Table 5 . In terms of clinical severity, there were significantly more patients with cardiogenic shock (18% vs 5%, p<0.05) in the H group than in the L group. There were also significantly more patients with ventricular arrhythmia in the H group (44% vs 18%, p<0.01). Looking at ST segment elevation resolution, significantly fewer patients showed significant ST segment resolution in the H group than in the L group (57% vs 96%, p<0.01).
The follow-up period for this study was 3 months. Seven patients died from cardiovascular causes during this period; heart failure was the cause in 5 of these, cardiac rupture in the case of 1, and sudden death out of hospital in 1 case. All 7 patients were in the H group. This is a significantly and remarkably higher mortality rate for H group than for the L group (7% vs 0%, p<0.01). Table 6 shows LV function in the chronic phase (21±8 days from onset). There were no significant differences in LVEDP between the 2 stages, but LVEF, RWM, and LVEDVI were all significantly poorer in the H group (LVEF: 51±15% vs 60±13%, p<0.01, RWM: -1.8± 1.4 SD/chord vs -1.3±1.6 SD/chord, p<0.05, LVEDVI: 74±19 ml/m 2 vs 66±14 ml/m 2 , p<0.05). Correlations between LVEF and ET values are shown in Table 3 . We observed a significant negative correlation between these (r=-0.40, p=0.003).
Discussion
Endothelin plays an important role in the vasoconstriction of the peripheral arterial system 14, 15 and of the coronary vascular bed. 16 Elevated plasma ET concentrations have been reported in patients suffering from diverse cardiovascular diseases, 17 including AMI. 11 In this study, we found that acute-phase plasma ET concentrations following successful direct PCI are closely related to LV systolic dysfunction and major adverse coronary complications, including death. In short, an acute-phase elevated plasma ET-1 concentration suggests a poor prognosis in patients with AMI.
We observed significantly more patients who failed to show ST-segment resolution in the H group than in the L group. Some reports 18, 19 have suggested that the absence of early ST-segment resolution after successful primary PCI identifies patients who are less likely to benefit from the recanalization of the infarct-related artery, because they are likely to have sustained greater microvascular injury and consequently have less salvageable myocardium. There may indeed be a close relationship between ET concentration and microvascular injury. Our study detected a significant negative correlation between ET concentration and LVEF in the chronic phase, and a close correlation between high ET-1 concentrations and LV remodeling. LV remodeling may be provoked by microcirculatory dysfunction following successful recanalization; that is to say, elevation in plasma ET-1 concentrations may reflect microvascular damage.
Our results also suggest that the ET-1 value shows a significant positive correlation with both BNP and hs-CRP. At present, it is generally recognized that acute-phase plasma concentrations of BNP are a useful predictor of clinical course, including mortality in the setting of AMI. 20, 21 BNP counteracts ET-1 by various physiological actions. In other words, increased BNP concentration may be described as a compensatory response to activated ET-1. Furthermore, some researchers have suggested that CRP concentrations are elevated in proportion to the clinical severity of AMI. 22, 23 AMI has an initial pathophysiological pathway, with plaque inflammation, rupture and intramural platelet thrombus being the mechanisms that kick-start the cascade of events leading to prolonged ischemia and eventually to myocardial necrosis. [24] [25] [26] Increased tissue ET-1 immunoreactivity inside coronary plaque has also been reported in patients with acute coronary syndrome. 27 The close relationship between plaque rupture and inflammation has been established already 28 and release of ET-1 is associated with the subsequent activation of the coagulation system. As a result, the ET-1 concentration in the acute phase of AMI may reflect the severity of the inflammation, which would imply that the value of ET-1 in acute-phase AMI is a useful predictive factor, likewise BNP and hs-CRP, for determining patient prognosis. In this study, the values of both BNP and hs-CRP showed a significant positive correlation with peak-CK (BNP; r: 0.52, p<0.001, hs-CRP; r: 0.40, p<0.01) despite there being no significant correlation between ET and peak CK. So BNP and hs-CRP may be more closely correlated with infarct size than ET. At the same time, however, we observed significantly more patients with DM in the H group than in the L group (46% vs 25%, p<0.05), despite neither BNP nor hs-CRP having any direct relation to DM. It has previously been established that there is a close relationship between DM and microvascular injury. 29 We also documented insufficient ST resolution among the H group patients. Ultimately, ET elevation can perhaps be thought to be a reflection of injury to the coronary microvascular circulation.
Certain previous reports have suggested that the origin of ET elevation in AMI cases may be in the pulmonary vascular bed rather than in the coronary vascular bed. 30.31 Our own results that point to the ET value showing a significant positive correlation with LVEDP in the acute phase also indicate that ET is elevated in accordance with pulmonary circulatory distress. However, our data also demonstrate a significant positive correlation between ET concentration and BNP, despite there being no significant correlation between ET and ANP, which implies that the origin of ET elevation may be more closely related to myocardial or coronary circulatory injury than to atrial or pulmonary circulatory injury. We also had 7 patients in our initial population who did not achieve TIMI 3 coronary flow after primary angioplasty and were subsequently excluded from our analysis because of the high possibility of poor LV function and prognosis. However, the ET concentrations in these patients were significantly higher than the average of the other patients (4.6±3.8 pg/ml). In addition the data also demonstrated that there were significantly more patients with multivessel coronary disease and that the number of coronary stents required to cover the culprit lesion was significantly larger in the H group than in the L group. These results suggest that the cause of elevated ET is closely tied to coronary circulatory distress. Furthermore, as previously described, in the H group we observed significantly more patients who failed to show ST-segment resolution than in L group and thus may conclude that the origin of the ET was the coronary vascular bed rather than the peripheral or pulmonary vascular bed.
This study has shown that a high ET-1 concentration in the acute phase of AMI may be closely associated with the severity of the patient's clinical condition, and even with mortality. Previous reports have suggested that immediately after an AMI or in ischemia -reperfusion injury models, the cardiac ET system is markedly activated and plasma concentrations of ET-1 increase. 11 There have also been reports that plasma ET-1 concentrations peak from several hours to 2 days after the onset of AMI 2, 27, 32 and that the ET concentration in AMI patients in particular reaches its peak value approximately 24 h after onset. 12 We considered that the peak value of ET was the most accurate indicator of the severity of AMI, which is why we took blood samples 24 h after onset. Another study has reported that ET-1 was elevated in proportion to the severity of heart failure. 33 In our study, there were significantly more patients with heart failure and cardiogenic shock in the H group than in the L group. At present, little is known, however, as to whether plasma levels of ET-1 are predictive of mortality in patients with AMI. We only observed cardiac death in the H group, which may mean that elevated ET-1 concentrations are not only an indicator of heart failure but also a predictor of cardiac mortality. In the acute phase of AMI, ET-1 works to preserve cardiovascular function through vasoconstriction, by maintaining blood supply and increasing cardiac output. 1 However, these functions influence cardiotoxicity by increasing afterload and pre-load over a long period, likewise activating the catecholamine or renin -angiotensin system. As has been discussed, ET-1 is also associated with microvascular dysfunction, an activated coagulation system, and inflammation. By virtue of the range of its physiological roles, increased plasma ET-1 concentrations may be closely related to cardiac mortality in the setting of AMI.
Study Limitations
First, the small size of the sample population means that our results require confirmation in a large-scale trial before any concrete significance can be extrapolated. Second, we excluded from the study patients with renal failure on the basis that these patients were not able to tolerate coronary angioplasty, which may have introduced bias into our results. Third, patients who died within 24 h of the onset of symptoms of AMI were also excluded, which may have constituted bias.
Conclusions
We have shown that acute-phase plasma ET-1 concentrations after successful direct PCI are closely related to LV systolic dysfunction and major adverse complications,
